Elite athletes, military veterans, first responders, and other high performers have a significantly higher risk of developing amyotrophic lateral sclerosis (ALS) than the general population, and a new study aims to find out why. The initiative, Champion Insights, is seeking up to…
Study probes high ALS risk in elite athletes and other ‘champions’
The first patient has been dosed in a Phase 1/2 clinical study of VTx-002, an experimental therapy being developed by VectorY Therapeutics for amyotrophic lateral sclerosis (ALS). The open-label PIONEER-ALS (NCT07287397) is enrolling up to 12 adults with ALS at sites in the U.S. and Europe. They will…
Origami Therapeutics is collaborating with Ipsen to develop experimental therapies designed to remove or correct abnormal proteins that build up in neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS). The partnership will focus on small molecules known as protein degraders and correctors. These compounds are designed to…
Coya Therapeutics has raised about $11.1 million in a private investment round to support commercial-readiness efforts for COYA 302, its experimental immune-modulating therapy being developed for amyotrophic lateral sclerosis (ALS). The funding was secured through the sale of more than 2.5 million company shares to two investors, the company…
A bipartisan team of U.S. lawmakers has reintroduced the ALS Better Care Act, a bill that aims to improve access to quality medical care for people with amyotrophic lateral sclerosis (ALS). The legislation was introduced in the House by Republican Brian Fitzpatrick of Pennsylvania and Democrats Jason Crow…
Last weekend, I left my husband, Todd, with a caregiver while I attended our daughter’s dance performance at Northern Michigan University. “Love Is A Burning Thing: A Johnny Cash Ballet” was the CO/LAB Dance Company’s tribute to Johnny Cash, featuring a number of his songs. The energy in…
Patient enrollment has reached the halfway mark in an ongoing expanded access program (EAP) for MN‑166 (ibudilast), Medicinova’s oral anti-inflammatory drug for the treatment of amyotrophic lateral sclerosis (ALS). EAPs, also known as compassionate use programs, are designed to help people with serious or life-threatening diseases receive experimental…
In the U.S., clinical trials for amyotrophic lateral sclerosis (ALS) do not include enough non-white patients and women to fully represent the disease’s landscape in the real world, a study found. This lack of representation of certain groups may prevent researchers from generalizing clinical trial findings to the overall…
Scientists have developed a way to grow motor neurons, the highly specialized nerve cells that are lost in amyotrophic lateral sclerosis (ALS), opening the door to new research avenues for treatment discovery. The new approach directs rare adult brain progenitor cells to become corticospinal-like neurons, a type of nerve…
After my late husband, Jeff, was diagnosed with ALS in the fall of 2018, I could not have managed without the help of other people, and he couldn’t have either. This is hard to write, but even harder to own. Asking for help used to be difficult for me.
Recent Posts
- Dealing with loss, both big and small, in life with ALS
- Scientists use fat-based ‘bubbles’ to sneak ALS treatment into the brain
- Guest Voice: ALS hasn’t stopped this go-to guy from showing up as ‘Dad’
- HEALEY ALS platform trial launches new arm testing oral therapy NUZ-001
- Ahead of this year’s MDA Conference, association’s CEO speaks of ‘hope’